|
⚲
|
| Keyboard |
| Vivo Capital LLC
✚
|
|
|---|---|
| CRD # | 159868 |
| SEC # | 801-79829 |
| CIK # | 0000167471, 0001674712 |
| AUM | 6,095.6 M (2026-03-31) |
| Employees | 62 (52% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 650-688-0818 |
| Address | 192 Lytton Avenue Palo Alto, CA 94301 |
| Source | [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn] [Facebook] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Fri, 31 Jul 2026 | Bright Minds Biosciences Inc. $DRUG Shares Bought by Vivo Capital LLC — MarketBeat |
| Fri, 31 Jul 2026 | Abivax SA Sponsored ADR $ABVX Shares Sold by Vivo Capital LLC — MarketBeat |
| Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 5 – Fees and Compensation
A. Interests in the Funds were only offered to “accredited investors” as defined in Rule 501 under
Regulation D promulgated under the Securities Act of 1933, as amended (the “Securities Act”), or
“qualified purchasers” as defined in the Investment Company Act of 1940, as amended (the
“Investment Company Act”). Vivo and/or its affiliates generally receive management fees and
performance fees for providing advisory services to the Funds. Investors and prospective investors
should refer to the Funds’ governing and offering documents for a detailed description of the fees and
expenses associated with investments in the Funds.
B. Vivo deducts management fees (the “Management Fee”) directly from the Funds’ assets paid
quarterly in advance. The Firm may also be entitled to a performance fee (the “Carried Interest”),
based on cumulative net profits from investments, as specified in each Fund’s governing and offering
documents. The Carried Interest, if applicable, is distributed directly from a Fund’s assets and not on
a pre-determined schedule. Management Fees will vary amongst the Funds.
C. Each Fund will bear all costs and expenses related to the purchase, holding, sale or exchange of
portfolio securities, Management Fee, Fund meetings, advisory committee matters, indemnification
obligations pursuant to the partnership agreement, liability and other insurance premiums for the
partnership, expenses associated with communications and reports, all legal, accounting and
regulatory filing fees relating to the Fund and its activities, and any extraordinary expenses of the
Fund.
Each Fund will also bear all costs and expenses related to the liquidation of the Fund’s assets upon
termination of the Fund. Investors and prospective investors should refer to the respective Funds’
governing and offering documents for a detailed description of the expenses borne by the Funds.
From time to time, in order to enhance the operations of a Vivo portfolio company and preserve and
increase the value of the portfolio company, Vivo’s employees may serve as “operating executives”
on a temporary basis of Vivo portfolio companies. In those occasions, the Vivo employee may enter
into a consulting or employment agreement with the portfolio company. Such operating executive’s
compensation from a portfolio company needs to be reasonable and commensurate with the role
that such operating executive plays at the portfolio company and is determined by the portfolio
company on an arm’s length basis. Vivo may also charge monitoring fees and/or transaction fees
where Vivo provides significant back-office support and business development for a portfolio
company, or syndicates a consortium for a buy-out transaction, and such monitoring fees and
transaction fees will offset the management fees of each applicable Fund in accordance with the
Fund’s governing documents.
Vivo’s employees may also serve on the boards of directors of Vivo portfolio companies and receive
director fees as a result. Those director fees will offset management fees of each applicable Fund in
accordance with the Fund’s governing documents.
Vivo Capital LLC Form ADV Part 2A Brochure 2026
D. Funds are generally required to pay Management Fees quarterly in advance, as specified in each
Fund’s governing and offering documents. In the event Vivo does not provide services for the full
period, the Management Fee is typically required to be returned to investors in the applicable Fund.
In general, the amount of fees returned is calculated based on the number of days remaining in the
applicable period.
E. Neither Vivo nor any of its supervised persons receive, directly or indirectly, any compensation from
the sale of securities or other investment products that were purchased by the Funds. |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure] |
|---|
Item 7 – Types of Clients Vivo provides investment advice to the Funds, which are private investment vehicles that are exempt from registration under the Investment Company Act. The Funds’ investors are limited to individuals and entities that meet certain suitability criteria including “accredited investors” and “qualified purchasers.” The Funds were marketed exclusively to institutional investors and high net worth individuals that meet these criteria. The minimum investment thresholds in the Funds range from $25,000 to $25 million; however, the minimum investment may be waived at the discretion of the General Partner of each Fund. Vivo and/or its affiliates have entered into separate agreements or arrangements (“Side Letters”) with certain investors in the Funds without the approval of any other investors. The Side Letters may offer certain investors additional or different rights or terms, including without limitation additional reporting obligations by the Funds to such investors, disclosure rights of such investors and/or confirmation as to whether an investor holds an advisory board seat. Also, the Side Letters will provide a customary most favored nation feature, which may include transparency of the side letters of other investors (or subset thereof) upon the final closing of the Fund. The Side Letters don’t offer investors with economic rights different from what is provided in the limited partnership agreement of the Funds. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Erasca Inc | 0.2 | ||
| Praxis Precision Medicines Inc | 0.1 | ||
| Trevi Therapeutics Inc | 0.1 | ||
| DBV Technologies Sa | 0.1 | ||
| Olivia Ventures Inc | 0.1 | ||
| BCTG Acquisition Corp | 0.0 | ||
| Big Cypress Acquisition Corp | 0.0 | ||
| Corvus Pharmaceuticals Inc | 0.0 | ||
| Bright Minds Biosciences Inc | 0.0 | ||
| Magenta Therapeutics Inc | 0.0 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Vivo Arrace Fund LP | [2025-03-31] | 321.3 M | |
| Filed 2024-07-08 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Vivo Asia Spring Limited | 2025-03-31 | 10.0 M | |
| PE | Vivo Capital Fund X LP | [2024-03-28] | 717.0 M | 755.1 M |
| Filed 2026-01-20 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Commission $100,000 · Revenue Decline to Disclose | ||||
| PE | Vivo Co-Invest C LP | [2024-03-28] | 150.0 M | |
| Filed 2023-10-27 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| Other | Vivo Asia Opportunity Fund Holdings LP | [2023-03-31] | 139.2 M | |
| Filed 2021-12-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| SA | Vivo Co-Invest S LP | [2023-03-31] | 49.8 M | |
| Filed 2022-04-13 (D) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration One year or less · Revenue Decline to Disclose | ||||
| VC | Vivo Innovation Fund II Holdings LP | [2023-03-31] | 180.0 M | 341.0 M |
| Filed 2022-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| Other | Vivo Opportunity Fund Holdings LP | [2023-03-31] | 1,998.9 M | |
| Filed 2021-12-16 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Vivo Asia Opportunity Fund LP | [2022-03-31] | 148.5 M | 105.4 M |
| Filed 2025-10-10 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| VC | Vivo Innovation Fund II LP | [2021-03-31] | 180.0 M | 209.0 M |
| Filed 2022-03-18 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 16 | 6.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 16 | 6.1 |
| By Discretionary | ||
| Discretionary | 16 | 6.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 16 | 6.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.4 | |
| United States Persons | 5.7 | |
| Total | 16 | 6.1 |
| Limited Partners | 2011 - 2026 |
|---|---|
| California State Teachers' Retirement System |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Chen Yu | Director | 24 | 3 | |
| Gaurav Aggarwal | Director, Executive Officer | 19 | 3 | |
| Albert Cha | Director, Executive Officer | 46 | 2 | |
| Frank Kung | Director, Executive Officer | 45 | 2 | |
| Jack Nielsen | Director | 44 | 2 | |
| Michael Chang | Director, Executive Officer | 38 | 2 | |
| Edgar Engleman | Director | 29 | 2 | |
| Mahendra Shah | Director, Executive Officer | 26 | 2 | |
| Hongbo Lu | Director | 17 | 2 | |
| David Liu | Director | 16 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001674712] | |
| 3 | [0001674712] | |
| 4 | [0001674712] | |
| SC 13D | [0001674712] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Vivo Capital LLC | Sinovac Biotech Ltd | [2018-07-11] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Private Equity |
| LEI | 25490014X9LPHXWXCC91 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 353,590 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 2,560,613 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 153,180 | $20.73 | 3,175,421 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 141,177 | $17.00 | 2,400,009 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 7,137 | $17.00 | 121,329 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Buy | 51,686 | $17.00 | 878,662 |
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 413,040 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Common Stock
|
2018-07-20 | Conversion | 57,035 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series A Preferred Stock · derivative
|
2018-07-20 | Conversion | 1,163,311 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series B Preferred Stock · derivative
|
2018-07-20 | Conversion | 1,358,903 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series B Preferred Stock · derivative
|
2018-07-20 | Conversion | 187,648 | ||
|
Crinetics Pharmaceuticals Inc CRNX
Series A Preferred Stock · derivative
|
2018-07-20 | Conversion | 8,424,416 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Riverwood Capital Management LP
✚
|
CA | 6,166.0 M |
|
Tikehau Capital North America LLC
✚
|
NY | 6,163.9 M |
|
A Fin Management LLC
✚
|
FL | 6,160.3 M |
|
Freeman Spogli Management Co LP
✚
|
CA | 6,160.3 M |
|
Lotus Infrastructure Partners LP
✚
|
CT | 6,155.6 M |
|
Primary Wave IP Investment Management LLC
✚
|
NY | 6,136.2 M |
|
Vision Ridge Partners LLC
✚
|
CO | 6,109.8 M |
|
Warren Equity Partners Manager LP
✚
|
FL | 6,088.1 M |
|
Haveli Investment Management LLC
✚
|
TX | 6,031.1 M |
|
Trivest Investment Advisors LLC
✚
|
FL | 6,011.2 M |